At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Aug 12, 2026 at 07:30 ET
Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership revenue recognition) and a net loss of $5.1M (-$0.03 EPS), in line with consensus. The quarter was overshadowed by the receipt of $178.4M from the Moderna settlement in July and a plan to return up to ~$230M to shareholders via share repurchases, alongside new LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and litigation catalysts, not the operational results.
- Received $178.4M from Moderna settlement in July 2026 as share of $950M noncontingent payment
- Plans to return up to ~$230M to shareholders via share repurchases, potentially including a Dutch Auction tender offer
- Filed three international LNP patent lawsuits against Pfizer/BioNTech across 21 countries
- Q2 2026 revenue $1.0M vs $10.7M YoY; net loss $5.1M (-$0.03 EPS) vs net income $2.5M ($0.01 EPS) YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access